Fox CB - Search Results

1

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations.

Baldwin SL, Reese VA, Larsen SE, Pecor T, Brown BP, Granger B, Podell BK, Fox CB, Reed SG, Coler RN. Baldwin SL, et al. Among authors: fox cb. Front Microbiol. 2022 Aug 26;13:935444. doi: 10.3389/fmicb.2022.935444. eCollection 2022. Front Microbiol. 2022. PMID: 36090093 Free PMC article.

2

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.

Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Fox CB, et al. Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):98-105. doi: 10.1016/j.colsurfb.2008.03.003. Epub 2008 Mar 22. Colloids Surf B Biointerfaces. 2008. PMID: 18440205

3

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.

Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS. Anderson RC, et al. Among authors: fox cb. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):123-32. doi: 10.1016/j.colsurfb.2009.08.022. Epub 2009 Aug 20. Colloids Surf B Biointerfaces. 2010. PMID: 19748238

4

Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.

Fox CB, Lin S, Sivananthan SJ, Dutill TS, Forseth KT, Reed SG, Vedvick TS. Fox CB, et al. Pharm Dev Technol. 2011 Oct;16(5):511-9. doi: 10.3109/10837450.2010.495397. Epub 2010 Jun 16. Pharm Dev Technol. 2011. PMID: 20550484

5

Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.

Fox CB, Friede M, Reed SG, Ireton GC. Fox CB, et al. Subcell Biochem. 2010;53:303-21. doi: 10.1007/978-90-481-9078-2_14. Subcell Biochem. 2010. PMID: 20593273

6

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Baldwin SL, et al. Among authors: fox cb. Vaccine. 2011 Jan 17;29(4):644-9. doi: 10.1016/j.vaccine.2010.11.043. Epub 2010 Dec 4. Vaccine. 2011. PMID: 21134451

7

Use of defined TLR ligands as adjuvants within human vaccines.

Duthie MS, Windish HP, Fox CB, Reed SG. Duthie MS, et al. Among authors: fox cb. Immunol Rev. 2011 Jan;239(1):178-96. doi: 10.1111/j.1600-065X.2010.00978.x. Immunol Rev. 2011. PMID: 21198672 Free PMC article. Review.

8

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG. Coler RN, et al. Among authors: fox cb. PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333. PLoS One. 2011. PMID: 21298114 Free PMC article.

9

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.

Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M. Lousada-Dietrich S, et al. Among authors: fox cb. Vaccine. 2011 Apr 12;29(17):3284-92. doi: 10.1016/j.vaccine.2011.02.022. Epub 2011 Feb 22. Vaccine. 2011. PMID: 21349366

10

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Fox CB, et al. Vaccine. 2011 Nov 28;29(51):9563-72. doi: 10.1016/j.vaccine.2011.08.089. Epub 2011 Sep 9. Vaccine. 2011. PMID: 21906648 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page